US drug sales growth continues slowdown in 2008

Mar 19, 2009

(AP) -- Sales growth of prescription drugs in the U.S. slowed for the second straight year, with the economic downturn playing a key role, according to IMS Health Inc.

Market research firm IMS cites lower demand for less-expensive generic drugs, lagging new product , and reduced consumer demand. Sales rose just 1.3 percent to $291 billion in 2008. That about matches IMS' prior outlook of 1 percent to 2 percent growth.

In 2007, U.S. sales rose 3.8 percent to $286.5 billion, while they gained 8 percent in 2006.

Anti-psychotic drugs were the lead sales drivers, followed by and treatments for heartburn and related conditions.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

World semiconductor sales up 5 percent

Nov 01, 2005

World semiconductor sales grew more than 5 percent in September as demand remained robust and driven by brisk markets for cell phones and personal computers.

Semiconductor sales down 28.6 pct in January: SIA

Mar 02, 2009

Worldwide semiconductor sales declined 28.6 percent in January from a year ago as the global recession continued to take a big bite out of the computer chip industry, an industry tracker said Monday.

Recommended for you

Added benefit of vedolizumab is not proven

30 minutes ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

23 hours ago

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0